Európska únia - chorvátčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutide - dijabetes mellitus, tip 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. prema rezultatima istraživanja u vezi kombinacije, utjecaj na glikemijski kontrolu i kardiovaskularnih događaja, a u ispitivanih skupina, vidi 4. 4, 4. 5 i 5.

Európska únia - chorvátčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - inzulin glargin - Šećerna bolest - lijekovi koji se koriste u dijabetesu - liječenje dijabetes melitusa kod odraslih, adolescenata i djece u dobi od 2 godine i više.

Európska únia - chorvátčina - EMA (European Medicines Agency)

gilead sciences ireland uc - кобицистат - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Európska únia - chorvátčina - EMA (European Medicines Agency)

gilead sciences ireland uc - Софосбувир - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 i 5. virus hepatitisa c (hcv) genotip određene aktivnosti, vidi 4. 4 i 5. sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 i 5. virus hepatitisa c (hcv) genotip određene aktivnosti, vidi 4. 4 i 5.

Európska únia - chorvátčina - EMA (European Medicines Agency)

teva generics b.v - monohidrat zoledronske kiseline - osteoporosis; osteitis deformans - bisfosfonati - liječenje osteoporosisin post-menopausal žene za odrasle Менат povećanog rizika od prijeloma, uključujući i posljednjih padove-ozljede prijeloma kuka . liječenje osteoporoze, povezan s dugoj sistemske glukokortikoidni terapiju nakon menopauze žene za odrasle Менат povećanog rizika od prijeloma. liječenje pagetova bolest kostiju kod odraslih osoba.

Európska únia - chorvátčina - EMA (European Medicines Agency)

teva b.v. - zoledronske kiseline - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - lijekovi za liječenje bolesti kostiju - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. liječenje pagetova bolest kostiju kod odraslih osoba.

Európska únia - chorvátčina - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Európska únia - chorvátčina - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Európska únia - chorvátčina - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant se može koristiti kao monoterapija ili u kombinaciji s metotreksatom. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Európska únia - chorvátčina - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - inzulin aspart - Šećerna bolest - lijekovi koji se koriste u dijabetesu - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.